Gamida Cell Ltd.

Harey Yehuda 54
P.O.B. 94
Savyon
56530

Tel: 03-534-7482
Fax: 03-534-3067

Show jobs for this employer

218 articles about Gamida Cell Ltd.

  • — Omidubicel represents a potentially transformative cell therapy treatment option for patients in need of a bone marrow transplant — —Newly presented data support clinical benefit demonstrated by primary and secondary endpoints— —Company anticipates BLA submission in second half of 2021—

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of the Phase 3 clinical trial of omidubicel will be presented for the first time at the TCT Meetings, the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blo

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in the offering was 9,343,750, inclusive of the full exercise of the underwriters’ option to purchase up to an additional 1,218,750 shares, at the pu

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Gamida Cell h

  •   - Focused on omidubicel, an advanced cell therapy, including a review of Phase 3 clinical data, and GDA-201, a natural killer cell therapy – - Event to feature an omidubicel patient’s perspective - - Live webcast on December 9, 2020 at 8:00 a.m. ET -

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for the quarter ended September 30, 2020.

  • Nov. 4, 2020 15:30 UTC Gamida Cell Announces Data to Be Presented at 62 nd ASH Annual Virtual Meeting – Updated data from Phase 1 Study of GDA-201 to be presented during an oral session – – New data on omidubicel in patients with severe aplastic anemia will also be presented –

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chief executive officer of Gamida Cell, will present at the H.C. Wainwright 6 th Annual Israel Conference on Thursday, November 12, 2020 at 11:00 a.m. ET. A live webcast of the pre

  • Gamida Cell and Be The Match BioTherapies ® Expand Strategic Collaboration – Organizations to work together to integrate Be The Match BioTherapies’ existing cell therapy infrastructure to manage the supply chain for potential commercialization of omidubicel –

  • Gamida Cell Ltd., an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced that the Phase 3 study of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant, met all three of its secondary endpoints.

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that company management will participate in three upcoming virtual investor conferences in September: H.C. Wainwright 22 nd Annual Global Investment Conference Date: Monday, September 14, 2020 Presentation: 11:00 a.m. ET Cantor Virtual Global Healthcare Confer

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a two-part virtual miniseries in September focused on key topics related to omidubicel , an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of a bone marrow transplant. The webcasts will take

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET (5:00 p.m. Israel time) at 12 Leshem Street, Kiryat Gat, 8258412, Israel. During the meeting, Julian Adams, Ph.D., Gamida Cell’s chief executive officer, will present an overview o

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, August 11, 2020, at 8:30 a.m. ET to review its second quarter 2020 financial results and provide an update on the company. The webcast will be available on the “Investors & Media” section of the Gam

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the appointment of Michele Korfin as chief operating and chief commercial officer. Ms. Korfin brings over 20 years of experience in oncology, focused on business operations and commercialization of novel therapies. In this role, she will have oversight of manufacturing and comm

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that David Fox has been appointed to Gamida Cell’s board of directors as an independent member. Mr. Fox brings significant leadership, company-building and business development experience to Gamida Cell’s board of directors as the company advances its clinical development candid

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will participate in a fireside chat at the JMP Securities Virtual Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:00 p.m. ET. A live webcast of the presentation will be available on the Investors sectio

  • Primary endpoint achieved in global, randomized, Phase 3 study of omidubicel; Initiation of BLA submission planned for fourth quarter of 2020 — – Additional data from GDA-201 program expected in second half of 2020 – – $60 million follow-on offering expected to close today – – Company to host conference call at 8:30 a.m. ET today – BOSTON--( BUSINESS WIRE )-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company com

  • Gamida Cell Ltd. announced the pricing of an underwritten public offering of 13,333,334 ordinary shares at a public offering price of $4.50 per share for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and estimated offering expenses.

  • Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Thursday, May 21, 2020, at 8:30 a.m. ET to review its first quarter 2020 financial results and provide an update on the company. The webcast will be available on the “Investors” section of the Gamida Cell websit